Bayer has agreed to collaborate with Arvinas on the targeted protein degradation of disease-causing proteins to develop therapeutics for a range of cardiovascular, oncological, and gynaecological diseases. The deal, worth up to US$749.5 M, combines Arvinas’ PROTAC® (Proteolysis-Targeting Chimera) protein degrader technology with Bayer’s expertise in these therapy areas to create both human therapeutics and agricultural solutions.